Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Castalin can boost the effectiveness of CHK1 inhibitors, a class of drugs currently in phase 1 clinical trials. When tested in cellular models of triple-negative breast cancer, one of the most aggressive forms of the disease, Castalin was shown to enhance the action of these inhibitors.
Clinical Pharmacology September 15th 2025
Cancer Therapy Advisor
These results suggest that PARP inhibition represents a potential treatment strategy in HRR-deficient advanced biliary tract cancer, including the potential platform to investigate novel combination treatment strategies as well as consideration for a more selective biomarker selection.
Gastroenterology September 15th 2025
Epoch Health
For every one-point increase in someone’s magnesium depletion score, their risk of depression rose by 13 percent… Lowering your magnesium depletion score, by improving your diet or addressing risk factors, may help prevent or even ease symptoms of depression.
Family Medicine/General Practice August 20th 2025
Conexiant
“The test is designed to assess a patient’s individualized risk of sentinel lymph node positivity and recurrence or metastasis, integrating tumor biology with clinical and pathological features via a validated proprietary algorithm.”
Dermatology August 18th 2025
Oncology Learning Network
The results of PROfound and PROpel underscore the importance of identifying the genomic characteristics of the patient and the cancer to guide the selection of the most appropriate treatment for a specific patient type.
Oncology, Medical April 29th 2025
The prevalence of HRR deficiencies has been found to be as high as 20% to 30% in patients with mCRPC, a significantly higher rate than that in patients with localized disease.
Oncology, Medical March 31st 2025